Top Bristol-Myers shareholder comes out against $74 billion Celgene deal

Bristol-Myers Squibb Co's top shareholder Wellington Management said on Wednesday it does not support the U.S. drugmaker's $74 billion deal to buy biotech Celgene Corp, imperiling what would be the largest pharmaceutical acquisition of all time.

from RSSMix.com Mix ID 8260657 https://ift.tt/2NykZZc